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Data Protection and Sample Management in Biobanking – A legal 
dichotomy 
 





Biobanking in Europe has made major steps towards harmonization and shared 
standards for the collection and processing of data and samples stored in biobanks. 
Still, biobanks and researchers face substantial legal difficulties in the field of data 
protection and sample management. Data protection law was harmonized almost 15 
years ago while rights in samples fall under the competence of the Member States of 
the EU. Despite the Data Protection Directive the field of data protection shows a 
substantial degree of deviation as public health was excluded from the harmonization. 
Biobanks seem to have substantially fewer difficulties to cope with in terms of the 
legal requirements in the field of sample management. This paper discusses the legal 
framework, experiences of different biobanks in Europe and potential ways forward. 
It also highlights the need for a health economic analysis of the costs and benefits of 
privacy protection in Europe. At the moment, policymakers seem to build their 
decisions on an insufficient evidence base which underestimates the potential value of 
biobanks for European public health. Within the past few years little progress has 
been achieved with regards to the development of a unified legal framework in 
Europe, The diversity in the legal system is also reflected in the different approaches 
of ethics committees towards biobanking. To secure the responsible and effective use 
of data and samples, more efforts are needed to come up with pathways for a solution.   
I. Introduction  
According to the OECD Guidelines,3 human biobanks and genetic research databases 
are structured resources that can be used for the purpose of genetic research which 
include: a) human biological materials and/or information generated from the analysis 
of the same; and b) extensive associated information. These research infrastructures 
have a high impact potential for public health and medicine, as new drug discovery 
and the development of so-called personalised medicine depend on the study of large 
collections of epidemiological, clinical and biological samples and information from 
large numbers of patients and healthy persons.4,5  
 
In March 2007 in Sevilla, the Institute for Prospective Technology Studies (IPTS), 
one of the seven institutes of the Joint Research Centre of the European Commission, 
and the Public Health Genomics European Network hosted the first workshop 
specifically addressing data protection issues in European biobanking. In January 
2010, experts from academia, industry and the European Commission convened in 
Sevilla again to discuss the development of the field in the previous three years. In the 
meantime, both biobanking and the science which uses biobanks made substantial 
progress. New disease-specific and population-based biobanks have been set up in 
Europe and around the globe. While the need for biobanks was still a matter for 
debate in 2007, there is now overall agreement in the research community that 
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biobanks are important tools for modern health research.6 This research in the field of 
genomics and systems biology is by nature a global enterprise which needs a global 
research infrastructure. The exchange of data and samples is vital for the future 
development of a modern knowledge society in the life sciences and public health. In 
this context, the legal framework for research and biobanks is of pivotal importance 
for the long-term sustainability of the biobanking enterprise and the success of Europe 
as a leading region for health research in the world.7, 8  
 
Both the normative sciences and the life sciences highlight privacy and data 
protection as core areas of the discourse.9 Researchers in the basic sciences and in 
clinical research may perceive privacy and data protection as limiting factors while 
normative sciences stress the importance of privacy and informational self-
determination as indispensable conditions of freedom in the information society.10 
The normative sciences, and in particular the field of public health genomics, aim to 
facilitate a discourse which, one would hope, proves that we do not face a trade-off 
between research as a collective good and privacy as a fundamental right. In this 
paper the current state of biobanking and the legal framework will be highlighted 
before the lack of economic evaluations is discussed. Finally, ways to move forward 
and opportunities for the exchange of samples and data are studied.  
II. Trends in biobanking in Europe 
In 2006 the IPTS conducted a survey of biobanks in Europe.11 The survey results 
paint a comprehensive portrait of biobanking activities in Europe: 145 active biobanks 
were identified and 72 per cent replied to the questionnaire (a total of 126 in 23 
countries). A more recent compilation, which may not follow the same 
methodological approach, can be found on the websites of international and European 
projects and networks.12 
  
According to the existing data, there has been acceleration in biobanking activities in 
recent years in Europe. While a few of the biobanks identified started collecting data 
in the 1970s, many more have been established relatively recently (during the 1990s), 
with 37 per cent of the surveyed biobanks starting their activity after 2000, obviously 
reflecting the burst of genome-wide association studies and the search for disease 
susceptibility genes and diagnostic biomarkers following the completion of the human 
genome sequencing project. The majority of the biobanks do not foresee an end to 
their sampling activities and indicate a high potential for growth, showing the 
dynamic nature of biobanking and an increasing role in research.  
 
About 80 per cent of the surveyed biobanks are public collections based either at 
universities or national/regional agencies and have been set up either for population-
based or disease-specific research purposes. Most of the collections are either small- 
or medium-sized and consist primarily of DNA, serum and whole blood and/or 
cellular tissue samples, and several types of associated data including medical, 
demographic, genetic and environmental.  
 
Interestingly, almost 70 per cent of the surveyed biobanks were single collections (ie 
not forming part of a network or partnership) with database systems which, in most 
cases, were stand-alone. In addition to this limited networking, at least in terms of 
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existing database infrastructures, only about half of the biobanks participating in the 
survey indicated they have a policy for sharing samples across borders either within 
the EU or worldwide. Nevertheless, access to the biobank is, in most cases, either 
entirely free or restricted to a part of the repository. Fees for granting access to 
samples and/or data apply to about a third of the cases. Yet scientific collaborations 
between biobanks are prominent. Eighty-five per cent of the survey respondents 
reported at least two collaborations with other researchers and 45 per cent reported 
more than 10. Moreover, 52 per cent of the biobanks surveyed are involved in 
international collaborations.  
 
Significant variability emerged with regards to privacy and data protection 
requirements among biobanks in Europe. The present survey demonstrates that the 
majority of biobanks have at least one type of consent form that allows tissue (63.5 
per cent) and data (69 per cent) sharing. Yet a significant proportion of them utilise 
more than one type of consent depending on the sample. The use of samples defined 
in the consent form is also highly varied, ranging from research on specific diseases to 
blanket (as practiced for example in the case of the UK Biobank). Importantly, 13 
respondents indicated that they do not apply consent at all.13 Six of them belong to 
Eastern European Countries with the rest based in Western Europe. 
 
Such differences have been observed previously and may be partly attributed to the 
varied interpretation and implementation of EC directives, and in particular the Data 
Protection Directive, EC Directive 95/46/EC,14 covering aspects of biobanking by 
national authorities. One of the main complications is that, although the field of data 
protection is harmonised through the EC directives, the collection, storage and sharing 
of samples is not. Furthermore, in countries that have introduced special biobanks acts 
it is not always clear where the borderline lies between the scope of these acts and that 
of the Directive. There seems to be a trend to break down this sample/data dichotomy 
and to consider under "database" both the physical sample and the information 
derived from it, but a deeper international understanding and agreement still need to 
be reached.  
 
As will be discussed, the variability found with regards to privacy and data protection 
requirements might reflect diverse interpretations of the EC directives by national 
authorities. However, it should be noted that, according to the survey, biobanks within 
the same country reported different practices, suggesting that the problems of 
harmonization might be greater than expected or acknowledged. Not only are there 
different national laws, but apparently even within EU Member States biobanks do 
not implement homogenous practices on privacy and data protection issues.  
 
The role of research ethics committees is, in this context, gaining increasing 
importance, as shown by the large majority of the biobanks surveyed which are 
governed by an ethics board (86 per cent). Properly addressing the ethical issues 
raised by vast biobanking projects can determine the successful clinical uptake of 
genomics. It is therefore important to understand how the different biobanks are 
dealing with these issues in practice. 
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III. The Data Protection Directive  
At the very heart of European data protection legislation is EC Directive 95/46/ECon 
the protection of individuals with regard to the processing of personal data and on the 
free movement of such data. It has been transposed into national law15 and serves as 
the basis for the national Data Protection Acts of all EU member states. Its objective 
is to secure the free flow of personal data within the internal market while ensuring a 
high level of protection for all citizens. Within the Directive and the national laws 
different categories of data exist which follow different regulatory pathways. These 
different pathways are also reflected in the 2009 OECD Guidelines on Human 
Biobanks and Genetic Research Databases.16, Health data are highly sensitive and 
therefore require a high level of protection.17 Health data are more than just data 
processed in the medical and health services. The categorisation depends on the 
purpose of the data processing; for example, data which have been collected to assess 
the socio-economic status of a person or which measure the exposure to 
environmental risks become health data if they are processed to study common-
complex disorders or health related behaviour.  Health data hold a special position 
within the Directive: the processing of sensitive data in general is prohibited (Article 
8). Still, the protection is not absolute and there are circumstances where the public 
interest overrides the privacy interests of the individual. For this reason some 
exemptions to the general prohibition to process health data are foreseen in the 
Directive. Biobanks as an infrastructure for research were still unknown at the time 
the Directive was drawn up, so it is not easy to find the right category for them. 
Biobanks are not research themselves but they belong to the wider research domain. 
Biobanks for health research can also be seen as public health tools as they share 
many legal features with monitoring and surveillance institutions.18  
 
Biobanks are not explicitly mentioned in Article 8; but the following paragraphs 
provide (or might provide) exemptions to the general processing prohibition relevant 
for biobanks and medical research:  
 
Paragraph 2 (a): the data subject has given his explicit consent to the 
processing of those data, except where laws of the Member State 
provide that the prohibition referred to in paragraph 1 (prohibition of 
processing of sensitive data) may not be lifted by the data subject’s 
giving his consent 
Paragraph 3: processing of person identifiable health data is allowed 
where this processing is required for the purpose of preventive 
medicine, medical diagnosis, the provision of care or treatment or 
the management of health-care services, and where those data are 
processed by a health professional subject, under national law or 
rules established by national competent bodies, to the obligation of 
professional secrecy, or by another person also subject to an 
equivalent obligation of secrecy.  
Paragraph 4: subject to the provision of suitable safeguards, Member 
States may, for reasons of substantial public interest, lay down 
exemptions in addition to those laid down in paragraph 2 either by 
national law or by decision of the supervisory authority.  
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Recital 34 to the Directive19 is related to Article 8(4). Here public health is explicitly 
mentioned, as being a legitimate ground for Member States to derogate from the 
prohibition on the processing of sensitive data.  
 
The implementation of the Directive in the Member States was monitored by the 
Directorate-General for Freedom, Security and Justice until a new division of 
responsibilities brought it under the aegis of the Directorate-General for Justice and 
Fundamental Rights. The first implementation report was published in 2003.20 The 
general conclusion was that there was no need for legislative change, although there 
was considerable scope for improvement in implementing the Directive. Currently a 
revision of the Directive is under discussion but the discourse is in an embryonic state 
and no conclusion can be made for the future of biobanking.  
III.2. The principles behind the Data Protection Directive  
III.2.1. The concept of purpose  
The concept of purpose is the basis of data protection and information rights in 
Europe as it serves as a litmus test  for the legitimacy of data processing (including 
the sharing and linking of data).  
 
The principle of purpose, in combination with the principles of non-excessiveness and 
fairness, with regard to data collections like biobanks is described in Recital 28 and in 
Article 6 para 1(b) of the Data Protection Directive. The wording of the Recital is: 
 
Whereas any processing of personal data must be lawful and fair to 
the individual concerned; whereas, in particular, the data must be 
adequate, relevant and not excessive in relation to the purposes for 
which they are processed: whereas such purposes must be explicit 
and legitimate and must be determined at the time of collection of 
the data; whereas the purposes of processing further to collection 
shall not be incompatible with the purposes as they were originally 
specified (our emphasis)  
 
The Recital highlights the data protection problems that biobanks are currently facing 
in the legal discourse. Large-scale population-based biobanks require substantial 
investments and are part of a long-term infrastructure for medical research. 
Accordingly, from the research perspective, the purpose is exactly to serve as a tool 
for long-term genome-based research.21 The Data Protection Directive states that the 
purpose of the processing must be legitimate and explicit at the time of the data 
collection.  
 
Not all biobanks are the same and the IPTS study clearly shows that small biobanks 
need to be taken into consideration as well: small size (e.g. university hospitals) and 
mid-size (e.g. pharmaceutical companies or disease-specific biobanks) biobanks 
which serve a specific research task face fewer difficulties in identifying a purpose in 
the sense of the Directive but they encounter other legal problems, such as access to 
information rights and return of information duties.The purpose issue has to be 
reconsidered once a small biobank enters into a virtual biobanking network or 
becomes an integral part of a bigger biobank. In contrast, large-scale biobanks may be 
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unable to define a specific scientific purpose at the time of the collection of data as 
they are open for various research protocols. The Directive does not provide an 
answer to the question whether the creation of an infrastructure for future genomic 
research is a legitimate, specific and explicit purpose. Large-scale biobanks tend to 
soften the privacy objections through procedural regulations and internal institutions 
which aim to guarantee a high level of privacy protection. Such surrogate solutions 
are widely accepted by politicians and donors, but still have to pass the litmus test of 
the Directive.   
 
The Directive itself acknowledges open purposes, as in Recital 3422 where 
derogations are allowed from the prohibition of processing on grounds of public 
health and social security. The exemption for scientific research in Recital 2923 only 
applies to the “further processing” of data and does not apply to the original data 
collection. An exemption which could be used by biobanks is the exemption foreseen 
in Art 8 para 3 with Recital 3324, which allows processing without an informed 
consent “for certain health-related purposes”. The applicability of Art 8 (3) is 
questionable, however, as the materials of the legislation process indicate that this 
exemption shall cover individual health purposes and the management of the health 
care system only.25 Therefore Recital 34 and the corresponding exemption of Art 8 
(4) need to be seen as the only legal basis for biobanks in the Directive. For politic
reasons Art 8 (4) is not harmonizing as it enables Member States to make exemptions:  
al 
 
Subject to the provision of suitable safeguards, Member States may, 
for reasons of substantial public interest, lay down exemptions in 
addition to those laid down in paragraph 2.  
 
While the Directive enables Member States to set up regulations which enable 
biobanks to achieve their goals, there is no harmonised legal situation in Europe. 
Member States are not obliged to use Art 8 (4) for biobanking purposes and if they do, 
they still have discretion how and to what extend they use it. The Directive also 
empowers Member States to define divergent safeguards which may force biobanking 
networks and multi-centre research studies using biobanks to follow a “gold standard” 
(in this case the strictest regulatory environment) approach whenever they want to 
transfer data.  
III.2.2 The concept of informational self-determination and informed Consent  
Privacy is often seen as the underlying concept of data protection policies in Europe. 
Yet privacy has different dimensions and, in particular with regards to data protection, 
also different roots in Europe. While privacy was originally seen as a right to be left 
alone, in particular in the Warren/Brandeis paper from 1890,26 its meaning has 
undergone substantial changes in the new information society. In 1983 the German 
constitutional court established  a “right to informational self-determination” which 
has influenced European data protection legislation ever since.27 This right implies 
that the individual shall have full knowledge about data processing processes which 
affect him or her. Informational self-determination serves not only the individual but 
also democracy and pluralism. From the idea of informational self-determination it is 
only a small jump to the consent model which is used in the Data Protection 
Directive. The concept of informational self-determination and the concept of purpose 
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interact in this context. To assess whether the collection of data and its further 
processing is necessary and proportionate, the purpose of the biobank must be taken 
into consideration. The definition of informed consent in the Data Protection 
Directive seems to support this view, as Art 2 (h) reads:  
 
The data subject`s consent shall mean any freely given specific  
and informed indication of his wishes by which the data subject 
signifies his agreement to personal data relating to him being 
processed. (our emphasis) 
 
The consent in data protection must be purpose-specific and informed, two 
prerequisites which are affiliated with each other, as the purpose also determines the 
content of the disclosure and information duties. This is important as many biobanks 
favour an open or blanket consent. Open or blanket in this sense means that the 
biobank can not specify the purpose; instead the donor is asked to consent to the use 
of material and data for all research proposals which fall under the scope of the 
biobank and which pass the ethical and legal check of the biobank. An open or 
blanket consent allows the biobank to operate more flexibly;  a specific consent 
procedure might force the bank to seek new donor consent for every study which 
wants to use data and material. Such a re-consent procedure cannot be handled by 
large biobanks and it also complicates the use of coding systems.  
 
There seem to be two main arguments which endorse the concept of blanket or open 
consent: firstly, the consent is buffered by further safeguards and a pluralistic 
governance system which includes different stakeholders and, secondly, donors may 
also be able to execute a “right to take a risk” which is a subcategory of the overall 
personality right. The “right to take a risk” can be accepted as a legal basis for 
open/blanket consent if the donors are fully informed about the incomplete degree of 
information they obtain during the disclosure process.28 This right to take a risk is not 
yet a widely accepted concept in the biobanking community or among data protection 
scholars, therefore the term should be used with caution. From the perspective of the 
right to informational self-determination as the German Constitutional Court 
developed it in the “Census Decision”, the open/blanket consent would still have to be 
deemed invalid as the donor is not put in a position where he/she can assess the future 
risks for privacy and the free development of the personality in the given information 
environment. The situation is even more complicated if the different layers of consent 
are considered, including the consent to sample collection and the consent to the 
medical research which will be carried out using the samples and data. In practice, 
biobanks have to manage primarily with the data protection consent if they work with 
samples and associated data. Any physical harm without consent must be deemed to 
be illegal and for the consent to research activities a broad consent is acceptable under 
the Directive if further safeguards protect the human subject .  
 
The current legal system offers both options as either the “right to take a risk” or the 
right to informational self-determination can be stressed. Both rights derive from the 
same source, human dignity and personality rights, although the “right to take a risk” 
could be seen to be derived from the overall concept of personality rights. The “right 
to take a risk” in this sense is a highly individualistic approach and may not 
correspond easily to the overall characteristics of certain kinds of genetic information. 
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Further elaboration is also needed as to what extent such a right is acceptable if the 
disclosure of information creates risks for third persons (in particular minors). 
Whenever the person who is consenting discloses identifiable information which 
relate to a second person and not solely to the person who has given the open/blanket 
consent, the “right to take a risk” can hardly be justified.29 Legal and ethical scholars 
advocating the “right to take a risk” need to work on additional concepts which enable 
society to govern such (potential) infringements of privacy rights of third persons.   
IV. The legal status of samples   
 Samples in the sense we use it here can mean various kinds of biological material 
including tissue, cells or blood. The legal situation of biological material varies across 
Europe.30 Under some legal systems, such as the German system, the donor retains 
property rights31 even after the biological material is permanently extracted from the 
body,32.while others have a different view. The English system, for example, does not 
apply property law to samples.33 
 
Under the Data Protection Directive the term 'data' is defined in Art 2 (a) in relation to 
the data subject: “Personal data shall mean any information relating to an identified or 
identifiable natural person (data subject).”  
 
Biological material, therefore, may not be seen as data under the Directive as it is not 
information itself. Like a hard drive, it contains data but another technical step is 
required to extract the data, in this case from the biological material.34 This may at 
first seem to be confusing. Take the example of blood. Blood is a liquid like many 
others and further analytical measures are needed to gain health information from the 
blood. The difference is even more apparent if we take the example of water; if a 
person drinks from a glass of water, it may be possible to extract genetic information 
about this person afterwards. Yet legal scholars would not even consider bringing the 
water under the definition of data in the Directive. Any data which accompany the 
samples, e.g. identification data, are of course information under the terms of the 
Directive.  
 
For samples, the Data Protection Directive becomes applicable if data are extracted 
from biological material in a way which could identify a person or within a setting 
which operates with identifiers. A biobank can serve as a research infrastructure and 
may not encounter data protection problems if it solely stores and ships biological 
material to a third party without any collection or secondary processing of personal 
information. For biobanks and researchers the combination of samples, data deriving 
from samples and secondary data is the key to the success of biobanking. Thus the 
legal separation of data and samples may appear artificial to them. Also, among legal 
scholars there is a growing tendency to apply the legal framework of data protection 
to both samples and data. The idea has recently been endorsed by the European Court 
of Human Rights in the case of  S. and Marper v. UK.35 This could eventually lead to 
a higher degree of harmonisation in Europe as the Directive governs substantial parts 
of the field. The European Commission does not have a direct competence to 
harmonize the legal framework for samples as this would affect the property rights 
domain. Although we face a huge diversity in the regulatory systems of samples and 
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data in Europe, it may not greatly affect the current practice of biobanking as data 
protection principles are frequently used as a benchmark for both data and samples.  
V. The application of a unified legal framework by ethics committees  
Medical research often requires an impartial review to make sure that research 
projects do not contravene ethical standards. Ethics committees, or institutional 
review boards (IRB) as they are called in many jurisdictions, serve this purpose. The 
involvement of such a committee can also help researchers to comply with the 
regulations of the Data Protection Directive, as Art 8 (4) / Recital 34 call for the 
provision of safeguards to protect the fundamental rights of data subjects. The 
borderline between data protection and the ethical approval of research projects is 
imprecise and some countries might even opt for a merger of both aspects.36 The 
interplay between the biobank and the recipient research group means that more than 
one ethics committee might be involved in the data and material transfer procedures. 
While the ethics committee of the recipient approves the research project, the biobank 
and its ethics committee may check compliance with the biobank’s own regulatory 
and ethics framework. Consequently, legal diversity in the data protection field is 
potentially amplified by the ethical values enforced by the different ethics 
committees.   
 
The interdisciplinarity of ethics committees guarantees that the various interests of 
researchers, donors and the public are balanced. One important area is the consent 
procedure, as the approval of an ethics committee may help to overcome the deficits 
of the open consent standard in biobanking, even though it cannot replace the 
individual consent which is based on the execution of fundamental rights.37 In the 
practice of biobanking, ethics committees may also act in a contrary way if they 
obstruct the free flow of data as intended by the Directive.38 This aspect has not been 
closely studied yet and needs further research. Due to its Single Market approach the 
Data Protection Directive forbids the erection of further hurdles for the sharing and 
linkage of data. Because of the rule of law doctrine and the hierarchy of norms in the 
legal system, this implies that neither national laws nor ethics committees are allowed 
to request higher standards of protection unless the higher standards are equally based 
on European law themselves.  
 
As Member States are obliged to implement the Directive they are entitled to ensure 
that ethics committees do not unnecessarily obstruct the access to data of researchers. 
While Art 8 (4) of the Directive empowers Member States to set up exemptions which 
lift the prohibition of sensitive health information there is no such rule which allows 
stricter regulations.  
VI. The lack of economic evaluation  
The issue of the cost of data protection is one of the arguments frequently indicated by 
the research community as a barrier to the development of basic science using 
biobanks. However, costs are often not acknowledged as a governance issue in 
genome-based research. It is also difficult to determine societal costs if research is not 
able to tap the full potential for the benefit of patients. Nevertheless, a clear analysis 
of the costs of data protection seems to be a necessary step to understand the actual 
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and potential impact of the Data Protection Directive, and to evaluate economic issues 
emerging from the application of data protection laws in Europe. 
 
Economic impact assessment has recently become a prominent issue in several policy 
fields and in particular in health.39 Since economic and cost-effectiveness 
considerations play an important role in the translational research (from basic 
discoveries to normative science) and in public health decision-making,40 it might be 
desirable for economic analysis to be applied to the study of data protection in 
biobanks. 
 
One of the core tasks of data protection is the promotion of ‘information justice’ 
which balances the individual right to privacy and the societal need for information in 
health research. As both the individual right to privacy and the collective/individual 
right to access to information have a value, they carry costs and benefits which should 
be carefully evaluated. 
 
Data protection explicitly erects hurdles which influence the costs of biobanking. For 
the practice of biobanking, new technical solutions like the GenoMatch41 model of 
BayerSchering might not be affordable for small or publicly financed biobanks. The 
requirement of an individual disclosure to donors, which derives from the donor-
centric disclosure standard in data protection, can also affect the costs of managing 
and using a biobank. According to preliminary estimates from BayerSchering, the 
costs for the triple coding procedures in GenoMatch vary between 20-30 Euros per 
sample. Costs of privacy protection might prohibit researchers from setting up small 
and midsize biobanks. These costs must be seen in relation to the expected public 
health benefits spinning off from the medical research made possible through the 
biobanks, and other intangible benefits, like public trust in health care and medical 
research and respect for citizens' privacy.  
 
Moreover data protection legislation, especially if not harmonized, could increase the 
cost of networking and sample/data sharing, thus limiting the (currently hypothetical) 
benefits from genomic research which uses large transnational collection of samples.  
 
However, data protection can also help biobanks to develop efficient procedures 
which might reduce costs in the long run. Moreover, from a biobank's perspective it 
should also consider the reduction in costs that the data protection law has on the 
recruitment of patients (potential donors). This should be done measuring the 
willingness-to-cooperate of the donors under alternative data protection regimes.  
  
No analysis of the cost-effectiveness of data protection in biobanking has been 
performed or published so far. This is linked to a lack of reliable and comparable 
economic data on biobanking activities. Indeed, there are few estimates of the costs of 
biobanks because of a number of issues, including the following: 
 
 Due to the lack of legal entity, the boundaries of biobanks for accounting 
purposes are difficult to define clearly. 
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 There are no accounting standards for biobanks’ activities, so it is not always 
straightforward to identify the relevant unit cost (i.e. cost per collected sample 
or cost per released sample) 
 The sensitivity to accounting and economic issues is very low among the 
scientists involved in the biobanks and, especially in the public ones, is not 
incentivised.  
 
On the ‘benefits’ side it is difficult to quantify, in economic terms, the possible 
innovations to which a biobank could contribute. Biobanks can be considered as basic 
research infrastructures, and the uncertainty of their potential results is exceptionally 
large in terms of time and magnitude. Morevoer, the actual "production" of a biobank, 
it is not easily quantifiable. There is still only limited agreement on whether 
considering scientific publications that quote a biobank as a source of data is a good 
proxy for evaluating biobanks' contribution to innovation and public health.  
 
The lack of economic data, the public nature of biobanks, and the significant positive 
externalities, as defined by Ertug et al,42 associated with biobank-based genomic 
research are all important barriers that might make it unrealistic to apply standard 
health economics analyses (e.g. cost-effectiveness analysis; cost-benefit analysis; 
cost-utility analysis) to the study of data protection in biobanks. Nevertheless, this 
should not limit the study of the economic implications of data protection in an 
important field of life science research and public health. Other types of policy impact 
analysis could be used to evaluate the economic impact of the Data Protection 
Directive on biobanks. These studies could be designed ad-hoc using survey on 
willingness-to-pay, under different data protection scenarios. It would be a major 
achievement if such a study could be conducted in the near future. 
VII. The way forward  
It seems evident, and widely recognised, that biobank quality, networking, and 
sustainability are critical to accelerating scientific discovery in the biomedical 
sciences. Building and sustaining biobanking infrastructures and finding ways to 
maximise their scientific value and international usage have become immediate goals.  
 
Ultimately, the success of tomorrow’s biobanking activities will depend upon creative 
problem-solving and will require a fundamental shift from working in disparate 
biobanks to a collaborative infrastructure and shared access approach.  
 
In the future, there is likely to be greater integration between the various biobank 
typologies (e.g., population, clinic, disease, and tissue), making data exchange more 
fluid between studies from isolated populations and from population-based and 
clinical-based biobanks 
 
New governance structures would be required to incorporate this option into the 
informed consent process and to define what information would be fed back, by 
whom, and how. Others argue that sharing individual results is unduly burdensome 
and thus impractical43. They further contend that participants are most interested in 
knowing simply that their involvement has enhanced scientific knowledge and served 
the public good. 
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Networking of biobanks is crucial for maximising their public health benefits. In order 
to be able to network these very different resources, some degree of harmonisation 
must be achieved. Whether this should be achieved at the level of legal/regulatory 
requirements and practices and/or by technical standardisation requires further 
investigation. Experts consulted in the IPTS study44 suggested the establishment of an 
international (rather than just European) umbrella (or network) organization, which 
would establish common operating procedures in, for example, genotyping and 
phenotyping, quality assurance and information management, and common 
approaches to ethical and legal requirements such as consent, data protection and 
privacy, feedback of information to donors, and so on. In this context, already existing 
initiatives with similar objectives should be taken into consideration. On a global level 
p3g45 and ISBER have been working in this domain and in Europe the recently 
established BBMRI has shown great efforts to take Europe to the next level of 
networking in biobanking.  
VIII. Conclusion  
Biomedical research in Europe still faces substantial problems when it comes to the 
exchange of samples and, in particular, data. While the Data Protection Directive 
serves as a benchmark for the exchange and flow of data, there seems to be no 
competence for the EU to govern the exchange of samples as this part of regulation 
falls under property law in many Member States. Interestingly, the problems in 
practice are rather observed in the field of data protection while samples are shipped 
routinely within the EU 27 and beyond. To some extent this situation arises from the 
fact that the field of public health is not harmonized in the Data Protection Directive. 
There is also a hypothesis that the data protection principles are interpreted differently 
in Member States and in particular amongst ethics committees and IRBs. This raises 
the question to what extent these boards and committees are empowered to set higher 
standards than those set out by law. In Europe, at least, such decisions should be made 
with respect to the overall aim of the Directive to enhance the exchange of data. Little 
evidence exists about the problems of commercial entities in obtaining data and 
samples for research. Big pharmaceutical companies run internal biobanks but 
apparently do not share facilities with academia. As big companies tend to operate 
under a global gold standard it is desirable to learn more about the procedures in 
industry.  
 
Recently, several countries have set up specific regulations for biobanking, 
biomedical research and the use of genome-based information. For the EU Member 
States these new regulations also have to be interpreted and assessed by applying the 
principles of the Data Protection Directive. Thus, two issues need to be raised: there is 
a strong need for a health-economic assessment of the societal costs versus benefits of 
data protection in biomedical research, and there is an urgent need for a strong 
European, or preferably global, institution which facilitates the exchange of both 
samples and data. The market approach as it seems to obtain currently in the field of 
samples cannot be the prime option for the entire domain of biobanking, as data 
protection is highly regulated and institutionalised around the globe. 
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